CMS proposes new drug pricing model to expand GLP-1 access to those with Medicare Part D and Medicaid
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth would increase access to glucagon-like peptide-1 (GLP-1) medications — used for weight loss and other health needs — and other healthy lifestyle interventions. As part of the BALANCE model, CMS will negotiate drug pricing and coverage terms on behalf of state Medicaid agencies and Medicare Part D plan sponsors.
State Medicaid agencies can join the model beginning May 2026, and Part D plans in January 2027.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
